Literature DB >> 35447875

A Lurking Threat of Community-Acquired Acinetobacter Meningitis-A Rare Case Report from Punjab, India.

Navodhya Jindal1, Sonia Jain2, Arghya Bhowmick3, Vyom Bhargava1.   

Abstract

Background: Acinetobacter spp. are a potential life-threatening cause of severe meningitis noted as a nosocomial infection after neurosurgical procedures in patients admitted to neurosurgical ICUs. Community-acquired Acinetobacter meningitis is extremely rare, and only a few cases have been reported in the literature. Case presentation: In this study, we report a patient from Punjab, India, who was infected after a roadside accident in which he developed CSF otorrhea and subsequent meningitis with Acinetobacter lwoffii. The patient was managed with the cephalosporin group of antibiotics as per the sensitivity report. For the first time, we report a rare case report of community-acquired Acinetobacter meningitis from Punjab, India. Conclusions: This case report highlights the potential pathogenicity of Acinetobacter lwoffii and increases concerns that this organism might rapidly evolve into a dreadful antibiotic-resistant community pathogen.

Entities:  

Keywords:  Acinetobacter; antibiotics; community-acquired; meningitis; nosocomial infection

Year:  2022        PMID: 35447875      PMCID: PMC9025329          DOI: 10.3390/medicines9040027

Source DB:  PubMed          Journal:  Medicines (Basel)        ISSN: 2305-6320


1. Introduction

The occurrence of community-acquired Acinetobacter meningitis of the central nervous system (CNS) is very rare [1,2]. Acinetobacter spp. are Gram-negative, opportunistic coccobacilli pertaining to the ESKAPE organisms that can accumulate diverse mechanisms of resistance, leading to the emergence of strains that are resistant to most of the commercially available antibiotics [3]. Moreover, the variable penetration of antibiotic agents through the blood–brain barrier into the cerebrospinal fluid (CSF) further limits the therapeutic choices for infections caused by Acinetobacter spp. [4]. Here, we present a striking case of community-acquired Acinetobacter meningitis in a patient from Moga, India, caused by the organism Acinetobacter lwoffii.

2. Case Presentation

The patient presented was brought with an alleged history of a roadside accident. The patient was hit by a car while riding on a motorcycle on 24 October 2021. The patient was found lying unconscious at the unhygienic corner of the road and was brought for emergency management. Emergency care was provided without delay. Initial examination revealed a body temperature of 38.9 °C, a blood pressure of 150/95 mm Hg, a heart rate of 110 beats/min and a respiratory rate of 16 breaths/min. An emergency computed tomographic (CT) scan of the head was conducted, which revealed a hairline fracture involving the right petrous temporal bone, as shown in Figure 1. The patient regained consciousness but was drowsy. His Glasgow Coma Score was found to be E4V4M6. The patient did not have any chronic disease and was not taking any form of medication prior to his admission. The patient did not have any known cases of diabetes, hypertension or hypothyroidism and was not addicted to any intravenous drugs. He was a smoker who smokes 1–2 cigarettes per day. Therefore, the immunological status of the patient was intact. No other comorbid history was present. The patient developed CSF leaks from both the ears after injury. The CSF leak from the right ear subsided spontaneously one day after the injury. However, the CSF leak from the left ear continued and increased initially.
Figure 1

CT scan image showing hairline fracture of the right petrous temporal bone of the patient.

3. Investigations

The timeline of infection aggravation and subsequent management is shown in Figure 2. On 28 October 2021, a CSF sample was taken from the left ear for a culture sensitivity test, which revealed the presence of Acinetobacter lwoffii sensitive to cefoperazone sulbactam, ceftriaxone sulbactam, meropenem, colistin, etc., as shown in Table 1. The antibiotic sensitivity test was conducted following the CLSI (Clinical and Laboratory Standards Institute, 2020) guidelines, an institute which is known to develop laboratory standards worldwide for medical testing [5]. Lumbar puncture was conducted the next day (29 October 2021) under all aseptic precautions, which revealed the same organism (Acinetobacter lwoffii) sensitive to the same group of antibiotics, confirming the presence of meningitis. The identification of the strain was further confirmed by 16S rDNA sequencing using universal sets of primers as described in previous studies [6]. The routine examination of the CSF sample showed that CSF proteins were raised to 155 mg/dL, with a normal level of glucose of 76 mg/dL. On the other hand, the CSF cell count was also raised to 1100 cells/cc, revealing neutrophilic pleocytosis consistent with the CT scan image of Acinetobacter meningitis, as shown in Figure 3.
Figure 2

Timeline of disease aggravation of the affected patient and subsequent management of the disease by proper antibiotic treatment. (CSF—Cerebrospinal Fluid, IV—Intravenous).

Table 1

Antibiogram profiling of Acinetobacter lwoffi showing sensitivity to various antibiotics (R—resistant; S—sensitive; IM—intermediate).

AntimicrobialsInterpretation
GentamycinR
CephalaxinR
AmikacinR
CiprofloxacinR
NetilmycinR
CefotaximeR
Ceftazidime + SulbactamR
OfloxacinIM
Cefoperazone + SulbactamS
AugmantinR
CotrimoxazoleR
MeropenemS
Pipercillin/TazobactumS
GatifloxacinS
CefuroximeR
CefiximeR
CefepimeR
CefprozilR
Ceftrixone + SulbactamS
ImipenemIM
ColistinS
ErtapenemR
EloresS
LevofloxacinS
Figure 3

Computed tomographic (CT) scan image showing diffuse hypodensities consistent with meningitis.

4. Treatment

The global treatment guidelines for bacterial meningitis were followed [7]. The patient was managed with an anti-meningitic dose of cefoperazone sulbactam 3 gm IV (intravenous) every 6 h. Cefoperazone sulbactam was used as the first-choice drug in this case as it is a narrow-spectrum antibiotic which is sensitive to the organism. Hence, there would be minimal chances of developing antibiotic resistance in the organism. It was used in anti-meningitic dosage which is always higher than the normal dosage of antibiotics. The sensorium of the patient was found to be improved. The CSF leak from the left ear subsided 10 days after the injury. Additionally, the patient was managed in the right lateral position with the left ear up with head end elevation.

5. Outcome and Follow-Up

Lumbar puncture of the patient was conducted after 4 days (3 November 2021) of continuous IV antibiotics. The CSF culture was found to be sterile with no growth of the organism, and also the cell count and protein level returned to normal. Intravenous (IV) antibiotics were continued for 21 days. The patient became alert, conscious and mobile, indicating complete improvement. At the follow-up, 15 days after discharge, the patient was found completely fit with no side effects.

6. Discussion

Acinetobacter meningitis is a life-threatening cause of acute pyogenic meningitis which is acquired mostly after any neurosurgical procedure and is resistant to most of the antibiotics [1,2]. Community-acquired cases of Acinetobacter meningitis are generally sensitive to most of the empirical antibiotics [8,9]. In this rare case, a patient from India developed Acinetobacter meningitis after trauma where no neurosurgical procedure was performed. To date, very few cases of Acinetobacter meningitis have been reported, and most are nosocomial infections which are acquired in the hospital ICU environment and are highly resistant to most of the commercially available antibiotics, leaving little choice of antibiotics to treat the infection [10,11]. This observed report of Acinetobacter meningitis by Acinetobacter lwoffii is a clear indication that the threat has moved far beyond the hospitals in India. Acinetobacter lwoffii may soon develop into a significant dreadful community pathogen in India.

7. Conclusions

Hospital-acquired Acinetobacter meningitis can be community-acquired too. The unscrupulous use of antibiotics should be avoided to prevent the development of highly resistant strains of Acinetobacter spp. so that all the narrow-spectrum and commercially available antibiotics can be targeted against them.
  10 in total

1.  ESCMID guideline: diagnosis and treatment of acute bacterial meningitis.

Authors:  D van de Beek; C Cabellos; O Dzupova; S Esposito; M Klein; A T Kloek; S L Leib; B Mourvillier; C Ostergaard; P Pagliano; H W Pfister; R C Read; O Resat Sipahi; M C Brouwer
Journal:  Clin Microbiol Infect       Date:  2016-04-07       Impact factor: 8.067

Review 2.  Community-acquired Acinetobacter meningitis in adults.

Authors:  W N Chang; C H Lu; C R Huang; Y C Chuang
Journal:  Infection       Date:  2000 Nov-Dec       Impact factor: 3.553

3.  Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome.

Authors:  Wah-Shing Leung; Chung-Ming Chu; Kay-Yang Tsang; Fu-Hang Lo; King-Fan Lo; Pak-Leung Ho
Journal:  Chest       Date:  2006-01       Impact factor: 9.410

Review 4.  Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.

Authors:  Roland Nau; Fritz Sörgel; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

5.  Community-acquired bacterial meningitis in adults: the epidemiology, timing of appropriate antimicrobial therapy, and prognostic factors.

Authors:  Cheng-Hsien Lu; Chi-Ren Huang; Wen-Neng Chang; Chin-Jung Chang; Ben-Chung Cheng; Ping-Yu Lee; Mei-Wen Lin; Hsueh-Wen Chang
Journal:  Clin Neurol Neurosurg       Date:  2002-09       Impact factor: 1.876

6.  A case of community-acquired Acinetobacter baumannii meningitis - has the threat moved beyond the hospital?

Authors:  Warren Lowman; Thomas Kalk; Colin N Menezes; Melanie A John; Martin P Grobusch
Journal:  J Med Microbiol       Date:  2008-05       Impact factor: 2.472

Review 7.  Community-acquired Acinetobacter infections.

Authors:  M E Falagas; E A Karveli; I Kelesidis; T Kelesidis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-12       Impact factor: 3.267

8.  Use of 16S rRNA gene for identification of a broad range of clinically relevant bacterial pathogens.

Authors:  Ramya Srinivasan; Ulas Karaoz; Marina Volegova; Joanna MacKichan; Midori Kato-Maeda; Steve Miller; Rohan Nadarajan; Eoin L Brodie; Susan V Lynch
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

Review 9.  Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review.

Authors:  Mansura S Mulani; Ekta E Kamble; Shital N Kumkar; Madhumita S Tawre; Karishma R Pardesi
Journal:  Front Microbiol       Date:  2019-04-01       Impact factor: 5.640

Review 10.  Carbapenemases: Transforming Acinetobacter baumannii into a Yet More Dangerous Menace.

Authors:  Maria Soledad Ramirez; Robert A Bonomo; Marcelo E Tolmasky
Journal:  Biomolecules       Date:  2020-05-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.